ArticleBMC oral health2026
Long-term oral and dental effects in childhood acute lymphoblastic leukemia survivors: a cross-sectional study comparing early and late post-treatment periods.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood cancer survivors face significant long-term oral health challenges following antineoplastic treatment. The primary aim of this study was to examine the effect of time elapsed since completion of antineoplastic treatment on oral health parameters - caries experience, salivary function, and dental developmental anomalies - in childhood ALL survivors. Secondary objectives included comparing oral health parameters between survivors and healthy sibling controls and identifying independent predictors of caries outcomes.
methodsThis cross-sectional study included 38 ALL survivors (aged 5-18 years) and 20 healthy sibling controls. Dental caries was assessed using the International Caries Detection and Assessment System (ICDAS II) and DMFT/dft indices. Salivary flow rate (SFR) and pH were measured using standardized protocols. Dental developmental anomalies were assessed by combined clinical and panoramic radiographic examination. Comparisons were performed using the Mann-Whitney U test, the Kruskal-Wallis test, and the chi-square test, with multivariable linear regression used to identify independent predictors of caries outcomes.
resultsEarly survivors demonstrated significantly higher mean ICDAS scores (median 1.38 vs. 0.60; p = 0.007) and elevated DMFT/dft indices (median 12.0 vs. 7.0; p = 0.002), together with significantly lower SFR (median 0.28 vs. 0.40 mL/min; p = 0.017), compared with late survivors. Dental developmental anomalies were significantly more prevalent in survivors (84.2%) than controls (10%; p < 0.001); microdontia was most common (37.7%), followed by root malformation (24.5%) and taurodontism (15.1%). Multivariable regression identified age and time since treatment completion as independent predictors of ICDAS scores (adjusted R² = 0.285, p = 0.014), while time since treatment completion independently predicted DMFT/dft scores (B = - 4.522, p = 0.003).
conclusionsDental developmental anomalies were highly prevalent among childhood ALL survivors and, being a direct consequence of treatment, were independent of the time elapsed since its completion. In contrast, salivary flow rate and caries experience were poorer among survivors examined within 24-36 months of treatment completion than among those examined later, indicating gradual recovery of salivary function over time. Closer preventive dental monitoring during the first years after treatment, supported by sustained oncology-dental collaboration, is therefore recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.